We performed a secondary analysis from the Cilostazol in Acute Ischemic Stroke Treatment ( CAIST ) trial , which was a double-blinded , randomized , multicenter trial , assessing the noninferiority of cilostazol over aspirin within 48 hours of an acute ischemic stroke .